Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion (COVE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04465461
Recruitment Status : Recruiting
First Posted : July 10, 2020
Last Update Posted : July 23, 2020
Sponsor:
Information provided by (Responsible Party):
Pulmonx Corporation

Brief Summary:
Prospective, multi-centre, pilot study aimed to evaluate the effect of Video Assisted Thoracic Surgery (VATS) fissure completion on the efficacy of endobronchial valve insertion (Zephyr Valve) in the treatment of subjects with severe Chronic Obstructive Pulmonary Disease (COPD) who exhibit collateral ventilation.

Condition or disease Intervention/treatment Phase
Pulmonary Emphysema Procedure: Video-assisted thoracoscopic surgery (VATS) fissure completion Device: Zephyr Valve insertion Not Applicable

Detailed Description:

The study will be a prospective, multi-centre, pilot study aimed to evaluate the effect of VATS fissure completion on the efficacy of endobronchial valve insertion (Zephyr Valve) in the treatment of subjects with severe COPD who exhibit collateral ventilation.

Study patients who provide informed consent and meet the initial inclusion/exclusion criteria following baseline screening assessments and multidisciplinary review to determine eligibility will undergo two procedures, not less than 28 days apart. The first procedure will involve an initial bronchoscopy and Chartis® assessment of collateral ventilation under general anaesthesia followed by a VATS fissure completion between targeted lobes in subjects that have collateral ventilation. The second procedure undertaken following fissure completion surgery will involve bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.

Subjects will be followed up over a 6-month period following VATS fissure completion and Zephyr® Endobronchial Valve (Zephyr Valve) insertion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of Video Assisted Thoracic Surgery (VATS) Fissure Completion Prior to Zephyr® Endobronchial Valve Insertion for Severe Chronic Obstructive Pulmonary Disease (COPD) in Patients With COllateral VEntilation
Actual Study Start Date : June 4, 2020
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : December 31, 2022

Arm Intervention/treatment
Experimental: Treatment
Patients exhibiting baseline collateral ventilation by Chartis® balloon catheter assessment who undergo video-assisted thoracoscopic surgery (VATS) fissure completion surgery, confirmation of fissure completion by computerized tomography (CT) scan and confirmation of conversion to collateral ventilation negative by Chartis® balloon catheter assessment post VATS surgery and subsequent Zephyr Valve insertion.
Procedure: Video-assisted thoracoscopic surgery (VATS) fissure completion
Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.

Device: Zephyr Valve insertion
Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
Other Name: Bronchoscopic Lung Volume Reduction (BLVR)




Primary Outcome Measures :
  1. Residual Volume (RV) [ Time Frame: 6 months ]
    Absolute Change in Residual Volume (RV) from baseline to 6-months post Zephyr Valve procedure.


Secondary Outcome Measures :
  1. Forced Vital Capacity (FVC) [ Time Frame: 6 months ]
    Absolute change in Forced Vital Capacity (FVC) from baseline to 6-months post Zephyr Valve procedure.

  2. Forced Expiratory Volume in 1 second/Forced Vital Capacity (FEV1/FVC) [ Time Frame: 6 months ]
    Absolute change in FEV1/FVC ratio from baseline to 6-months post Zephyr Valve procedure.

  3. Total Lung Capacity (TLC) [ Time Frame: 6 months ]
    Absolute change in Total Lung Capacity (TLC) from baseline to 6-months post Zephyr Valve procedure.

  4. Six-Minute Walk Test (6MWT) [ Time Frame: 6 months ]
    Absolute change in Six-Minute Walk Test (6MWT) from baseline to 6-months post Zephyr Valve procedure.

  5. St. George's Respiratory Questionnaire (SGRQ) Total Score [ Time Frame: 6 months ]
    Absolute change in the St. George's Respiratory Questionnaire Total Score from Baseline to 6-months post Zephyr Valve procedure. The St. George's Respiratory Questionnaire measures health status (quality of life) in patients with diseases of airways obstruction. Scores range from 0 to 100, with higher scores indicating more limitations.

  6. Modified Medical Research Council (MMRC) Score [ Time Frame: 6 months ]
    Absolute change in the modified Medical Research Council (MMRC) Score from Baseline to 6-months post Zephyr Valve procedure. The mMRC (Modified Medical Research Council) stratifies severity of dyspnea in respiratory diseases. The severity of dyspnea is rated on a scale of 0 to 4, with higher scores indicating more limitations.

  7. Forced Expiratory Volume in 1 second (FEV1) [ Time Frame: 6 months ]
    Percent change in FEV1 from baseline to 6-months post Zephyr Valve procedure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is willing and able to provide informed consent and to participate in the study.
  2. Subject is ≥ 40 years of age.
  3. Subject has a diagnosis of severe or very severe homogenous or heterogeneous COPD (Global Initiative for Obstructive Lung Disease (GOLD) classification).
  4. Subject has a post bronchodilator 15% ≤ FEV1 ≤ 50%.
  5. Subject has Total Lung Capacity (TLC) ≥ 100% predicted.
  6. Subject has Residual Volume (RV) ≥ 150% predicted.
  7. Subject has a normal dobutamine stress echocardiogram.
  8. Subject has sufficient exercise tolerance i.e. 150m ≤ 6MWT ≤ 450m.
  9. Subject has an incomplete lobar fissure i.e. < 90%, as confirmed by CT evaluation of lung fissures.
  10. Collateral ventilation confirmed as assessed by Chartis Assessment (to be confirmed during first procedure/operation)
  11. Subject has stopped smoking for at least 8 weeks prior to entering the study as confirmed by carboxyhaemoglobin or cotinine levels.
  12. Subject is up to date with preventive vaccinations including seasonal influenza vaccine and pneumococcal vaccine consistent with the Victorian Department of Health and Human Services Immunization Schedule Guidelines (updated March 2018).

Exclusion Criteria:

  1. Subject has a history of previous thoracotomy, lung volume reduction surgery, prior lobectomy or pneumonectomy, prior lung transplantation, prior airway stent placement, prior pleurodesis, or prior endobronchial lung volume reduction therapy of any form.
  2. Subject has an acute COPD exacerbation.
  3. Subject has evidence of active respiratory infection.
  4. Subject has a post bronchodilator FEV1 < 15%.
  5. Subject has a Diffusing capacity for carbon monoxide (DLCO) < 20%.
  6. Subject has a history of recurrent clinically significant respiratory infections, defined as three (3) or more COPD exacerbations requiring hospitalization during the 12 months prior to study enrollment (Informed Consent Form signature page).
  7. Subject has severe gas exchange abnormalities as defined by any one of the following:

    1. Partial pressure of oxygen (PaO2) < 60 mmHg
    2. Partial pressure of carbon dioxide (PaCO2) > 45 mmHg
    3. Oxygen saturation (SpO2) < 90% on ≥ 4 L/min supplemental O2 at rest
  8. Subject use of systemic steroids > 20mg/day or equivalent and/or immunosuppressive agents in the 4 weeks prior to procedure.
  9. Subject unable to temporarily interrupt use of heparins or oral anticoagulants or antiplatelet agents, excluding aspirin.
  10. Subject's pre-operative CT scan indicates the presence of any of the following radiological abnormalities:

    1. Pulmonary nodule ≥ 0.8 cm in diameter (does not apply if present for 2 years or more without increase in size or if proven benign by biopsy/positron emission tomography (PET)).
    2. Radiological picture consistent with active pulmonary infection, e.g. unexplained parenchymal infiltrate.
    3. Giant bullae > 30% of the volume of either lung.
    4. Significant interstitial lung disease.
    5. Significant pleural disease.
  11. Subject's baseline electrocardiogram (ECG) demonstrates clinically significant arrhythmias or conduction abnormalities.
  12. Clinically significant asthma (reversible airway obstruction), chronic bronchitis or bronchiectasis.
  13. Subject has a known diagnosis of alpha-1 antitrypsin deficiency.
  14. Subject is classified as having "likely" pulmonary hypertension defined as tricuspid regurgitation velocity > 3.4m/s and/or pulmonary artery peak systolic pressure > 45 mmHg on echocardiogram or a previous formal diagnosis of pulmonary hypertension on right heart catheterization.
  15. Subject has suspected significant coronary artery disease defined as regional wall motion abnormalities on dobutamine stress echocardiogram.
  16. Subject is classified as being at major cardiac risk with the presence of unstable coronary syndromes (i.e. unstable or severe angina or recent myocardial infarct), decompensated heart failure, significant arrhythmias or severe valvular disease, which warrants intensive management of the condition in accordance with current guidelines on perioperative cardiovascular risk.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04465461


Contacts
Layout table for location contacts
Contact: Carla Martins 650-216-0176 cmartins@pulmonx.com
Contact: Diana Dobbs 650-216-0172 ddobbs@pulmonx.com

Locations
Layout table for location information
Australia, Victoria
St. Vincent's Hospital Melbourne Recruiting
Fitzroy, Victoria, Australia, 3065
Contact: Jane Mack    +613 9231 4615    jane.mack@svha.org.au   
Principal Investigator: Naveed Alam, Mr         
St. Vincent's Private Hospital Fitzroy Recruiting
Fitzroy, Victoria, Australia, 3065
Contact: Jane Mack    +61 3 9231 4615    jane.mack@svha.org.au   
Principal Investigator: Naveed Alam, Mr         
Sponsors and Collaborators
Pulmonx Corporation
Investigators
Layout table for investigator information
Principal Investigator: Naveed Alam, MD St Vincent's Hospital Melbourne
Layout table for additonal information
Responsible Party: Pulmonx Corporation
ClinicalTrials.gov Identifier: NCT04465461    
Other Study ID Numbers: 630-0026-01
First Posted: July 10, 2020    Key Record Dates
Last Update Posted: July 23, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Emphysema
Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases